XEN-101 is under clinical development by Xeno Biosciences and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XEN-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XEN-101 is under development for the treatment of obesity. It is administered through oral route in the form of capsule.
Xeno Biosciences overview
Xeno Biosciences is a biotechnology company provider of novel class of treatments for metabolic diseases. The company is headquartered in Cambridge, Massachusetts, the US
For a complete picture of XEN-101’s drug-specific PTSR and LoA scores, buy the report here.